5-HT2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits

Xuemei Huang, David E. Nichols

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

The hypothesis was tested that serotonin (5-HT) modulates 3,4-methylenedioxymethamphetamine (MDMA)-induced increase in dopamine synthesis. Rats were treated with the selective 5-HT2 receptor agonist (R)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (R-DOI), the selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan (MMAI), amphetamine, MDMA, or a combination of amphetamine and R-DOI or MMAI, followed by the L-dihydroxyphenylalanine (DOPA) decarboxylase inhibitor 3-hydroxybenzylhydrazine (NSD-1015). Rats were killed 45 min after the first injection and striatal DOPA was determined. R-DOI, NMAI, or amphetamine alone did not increase DOPA accumulation. However, combination of amphetamine with either MMAI or R-DOI significantly increased DOPA accumulation. Multiple doses of the R-DOI and amphetamine combination did not decrease [3H]paroxetine binding sites at one week after killing. The results indicate that the dopamine synthesis increasing effect of MDMA depends both on 5-HT2 receptor stimulation and dopamine efflux.

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalEuropean Journal of Pharmacology
Volume238
Issue number2-3
DOIs
StatePublished - Jul 20 1993

All Science Journal Classification (ASJC) codes

  • Pharmacology

Fingerprint Dive into the research topics of '5-HT<sub>2</sub> receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits'. Together they form a unique fingerprint.

  • Cite this